Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short Interest

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,860,000 shares, an increase of 118.9% from the September 15th total of 849,700 shares. Currently, 4.4% of the company's stock are short sold. Based on an average daily volume of 473,800 shares, the short-interest ratio is presently 3.9 days.

Zura Bio Stock Up 5.2 %

NASDAQ:ZURA traded up $0.20 during trading hours on Friday, reaching $4.06. 145,460 shares of the company's stock were exchanged, compared to its average volume of 323,066. The company has a 50-day moving average of $3.83 and a 200 day moving average of $3.88. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.86.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sell-side analysts predict that Zura Bio will post -0.47 EPS for the current year.

Insider Buying and Selling at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now directly owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 22.10% of the company's stock.

Institutional Trading of Zura Bio

Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth $62,000. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $8,446,000. Forefront Analytics LLC increased its holdings in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock valued at $145,000 after purchasing an additional 7,531 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $43,000. Finally, Armistice Capital LLC increased its holdings in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

Analysts Set New Price Targets

ZURA has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Thursday, August 15th. HC Wainwright began coverage on shares of Zura Bio in a research note on Thursday, September 5th. They set a "neutral" rating and a $5.00 price target for the company. Finally, Piper Sandler reiterated an "overweight" rating and set a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.